Ultralife Co. (NASDAQ:ULBI - Get Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 181,100 shares, a growth of 19.3% from the November 30th total of 151,800 shares. Based on an average daily trading volume, of 65,200 shares, the short-interest ratio is currently 2.8 days. Approximately 1.8% of the company's stock are short sold.
Ultralife Stock Down 1.5 %
ULBI traded down $0.11 during midday trading on Friday, hitting $7.29. 46,380 shares of the company's stock traded hands, compared to its average volume of 76,976. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.30 and a quick ratio of 1.62. The company has a market cap of $121.21 million, a PE ratio of 13.25 and a beta of 0.95. The stock's fifty day simple moving average is $7.95 and its 200-day simple moving average is $9.37. Ultralife has a one year low of $6.36 and a one year high of $13.39.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers raised its stake in shares of Ultralife by 1,728.3% in the 2nd quarter. Rhumbline Advisers now owns 11,811 shares of the technology company's stock valued at $125,000 after acquiring an additional 11,165 shares in the last quarter. Barclays PLC grew its holdings in Ultralife by 21.3% during the third quarter. Barclays PLC now owns 13,395 shares of the technology company's stock valued at $121,000 after purchasing an additional 2,355 shares during the last quarter. Juncture Wealth Strategies LLC bought a new position in shares of Ultralife in the third quarter valued at approximately $165,000. Jane Street Group LLC acquired a new stake in shares of Ultralife in the third quarter worth $166,000. Finally, XTX Topco Ltd boosted its holdings in shares of Ultralife by 192.1% during the 2nd quarter. XTX Topco Ltd now owns 37,399 shares of the technology company's stock worth $397,000 after buying an additional 24,595 shares during the period. Institutional investors own 30.68% of the company's stock.
Analysts Set New Price Targets
A number of research firms have recently weighed in on ULBI. StockNews.com downgraded shares of Ultralife from a "strong-buy" rating to a "buy" rating in a research note on Thursday, October 3rd. Benchmark reaffirmed a "buy" rating and issued a $14.00 target price on shares of Ultralife in a research report on Friday, November 15th.
Check Out Our Latest Research Report on Ultralife
About Ultralife
(
Get Free Report)
Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.
See Also
Before you consider Ultralife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.
While Ultralife currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
